Monumental-6: A Phase 3 Study of Talquetamab plus Pomalidomide or Talquetamab plus Teclistamab Vs Elotuzumab plus Pomalidomide plus Dexamethasone (EPd) or Pomalidomide plus Bortezomib plus Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

被引：0
|
作者：
Nooka, Ajay K.
Mian, Hira [1 ]
Lee, Cindy [2 ]
Rodriguez-Otero, Paula [3 ]
Kumar, Shaji [4 ]
Einsele, Hermann [5 ]
Vishwamitra, Deeksha [6 ]
Vieyra, Diego [6 ]
Kane, Colleen [6 ]
Kosh, Michele [6 ]
Masterson, Tara J. [6 ]
Heuck, Christoph [7 ]
Kansagra, Ankit [7 ]
Moreau, Philippe [8 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[2] McMaster Univ, Hamilton, ON, Canada
[3] Royal Adelaide Hosp, Adelaide, Australia
[4] Clin Univ Navarra, Madrid, Spain
[5] Mayo Clin, Div Hematopathol, Rochester, MN USA
[6] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[7] Janssen Res & Dev, Spring House, PA USA
[8] Univ Hosp, Nantes, France
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-199752
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：47571 / 47572
页数：2
相关论文
共 50 条
  • [31] Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/ Refractory Multiple Myeloma and 17p Deletion
    Montefusco, Vittorio
    Cafro, Anna Maria
    Casaluci, Gloria Margiotta
    Patriarca, Francesca
    Mina, Roberto
    D'Agostino, Mattia
    Capra, Andrea
    Priola, Claudia
    Dalla Palma, Anna Benedetta
    Rizzi, Rita
    Genua, Angelo
    Petrucci, Maria Teresa
    Paris, Laura
    Belotti, Angelo
    Cavo, Michele
    Conticello, Concetta
    Carlo-Stella, Carmelo
    Boccadoro, Mario
    BLOOD, 2022, 140 : 10193 - 10195
  • [32] Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3trial
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Baldini, Luca
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria -Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Kampfenkel, Tobias
    Liu, Weiping
    Wang, Jianping
    Kosh, Michele
    Tran, Namphuong
    Carson, Robin
    Sonneveld, Pieter
    LANCET HAEMATOLOGY, 2023, 10 (10): : E813 - E824
  • [33] Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study
    Weisel, Katja
    Paner, Agne
    Engelhardt, Monika
    Taylor, Fiona
    Cocks, Kim
    Espensen, Ashlee
    Popa-McKiver, Mihaela
    Chen, Clara
    Cavo, Michele
    BLOOD, 2018, 132
  • [34] Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
    Schjesvold, Fredrik H.
    Dimopoulos, Meletios-Athanasios
    Delimpasi, Sosana
    Robak, Pawel
    Coriu, Daniel
    Legiec, Wojciech
    Pour, Ludek
    Spicka, Ivan
    Masszi, Tamas
    Doronin, Vadim
    Minarik, Jiri
    Salogub, Galina
    Alekseeva, Yulia
    Lazzaro, Antonio
    Maisnar, Vladimir
    Mikala, Gabor
    Rosinol, Laura
    Liberati, Anna Marina
    Symeonidis, Argiris
    Moody, Victoria
    Thuresson, Marcus
    Byrne, Catriona
    Harmenberg, Johan
    Bakker, Nicolaas A.
    Hajek, Roman
    Mateos, Maria-Victoria
    Richardson, Paul G.
    Sonneveld, Pieter
    LANCET HAEMATOLOGY, 2022, 9 (02): : E98 - E110
  • [35] Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Baldini, Luca
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria-Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Kampfenkel, Tobias
    Liu, Weiping
    Kosh, Michele
    NamPhuong Tran
    Carson, Robin
    Sonneveld, Pieter
    BLOOD, 2022, 140 : 7272 - 7274
  • [36] Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
    Mateos, Maria-Victoria
    Blacklock, Hilary
    Schjesvold, Fredrik
    Oriol, Albert
    Simpson, David
    George, Anupkumar
    Goldschmidt, Hartmut
    Larocca, Alessandra
    Chanan-Khan, Asher
    Sherbenou, Daniel
    Avivi, Irit
    Benyamini, Noam
    Iida, Shinsuke
    Matsumoto, Morio
    Suzuki, Kenshi
    Ribrag, Vincent
    Usmani, Saad Z.
    Jagannath, Sundar
    Ocio, Enrique M.
    Rodriguez-Otero, Paula
    San Miguel, Jesus
    Kher, Uma
    Farooqui, Mohammed
    Liao, Jason
    Marinello, Patricia
    Lonial, Sagar
    LANCET HAEMATOLOGY, 2019, 6 (09): : E459 - E469
  • [37] Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma
    Richardson, Paul G.
    Hungria, Vania T. M.
    Yoon, Sung-Soo
    Beksac, Meral
    Dimopoulos, Meletios A.
    Elghandour, Ashraf
    Jedrzejczak, Wieslaw Wiktor
    Guenther, Andreas
    Thanyaphong Na Nakorn
    Siritanaratkul, Noppadol
    Schlossman, Robert L.
    Hou, Jian
    Moreau, Philippe
    Lonial, Sagar
    Lee, Jae Hoon
    Einsele, Hermann
    Salwender, Hans
    Sopala, Monika
    Panneerselvam, Ashok
    Redhu, Suman
    Corrado, Claudia
    Binlich, Florence
    San Miguel, Jesus F.
    BLOOD, 2014, 124 (21)
  • [38] GLOBAL SURVIVAL (SG) OF PATIENTS WITH MULTIPLE MYELOMA IN RELAPSED OR REFRACTORY (MMRR) WITH CARFILZOMIB plus DEXAMETHASONE (KD) VS BORTEZOMIB plus DEXAMETHASONE (VD) IN RANDOMIZED PHASE 3 ENDEAVOR STUDY
    Oriol, A.
    Dimopoulos, M.
    Goldschmidt, H.
    Niesvizky, R.
    Joshua, D.
    Chng, W. J.
    Orlowski, R. Z.
    Feng, S.
    Kimball, A. S.
    Moreau, P.
    HAEMATOLOGICA, 2017, 102 : 19 - 19
  • [39] Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)
    Chng, Wee J.
    Kim, Kihyun
    Huang, Jeffrey
    Chim, Chor Sang
    Kosugi, Hiroshi
    Takezako, Naoki
    Sakamoto, Junichi
    Gopalakrishnan, Sathish Kumar
    Wei, Yuan
    Zhuo, Ling Ying
    Lee, Je-Jung
    Yoon, Sung-Soo
    Kim, Jin Seok
    Min, Chang-Ki
    Lee, Jae-Hoon
    Durie, Brian G. M.
    BLOOD, 2016, 128 (22)
  • [40] A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.
    Mateos, Maria-Victoria
    Blacklock, Hilary
    Schjesvold, Fredrik
    Rocafiguera, Albert Oriol
    Simpson, David
    George, Anupkumar
    Goldschmidt, Hartmut
    Larocca, Alessandra
    Sherbenou, Daniel Wayne
    Avivi, Irit
    Iida, Shinsuke
    Matsumoto, Morio
    Usmani, Saad Zafar
    Jagannath, Sundar
    Rodriguez-Otero, Paula
    Kher, Uma
    Farooqui, Mohammed Z. H.
    Liao, Jason
    Marinello, Patricia
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345